Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance
Saturday, March 7, 2026, 12:22 am / permalink 20306 / 4 stories in 4 days
Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.